6 days ago · Study uncovers why PF after severe COVID-19 doesn’t progress. An imbalance in gene activity within two types of immune cells explains why idiopathic pulmonary fibrosis (IPF) progresses but in people who develop lung fibrosis after a severe COVID-19 infection, their lungs get better, a new study finds.

Apr 26, 2024 · The study provides pharmacological proof of concept for an upcoming Phase 1 clinical trial that’s evaluating CMR316, an investigational inhalable therapy similar to the designed prototype. “Most drugs act by slowing the progression of disease; our approach is to make drugs that control cell fate to stop or reverse the disease process,” Peter G. Schultz, PhD, president and CEO of Scripps ...

Aug 16, 2019 · To address some misconceptions about the prognosis of pulmonary fibrosis and life expectancy of patients, we’ve put together some frequently asked questions (and answers) to help:<. What causes pulmonary fibrosis? Some cases of pulmonary fibrosis occur without known cause (this is called idiopathic pulmonary fibrosis).Other cases are caused by exposure to environmental hazards (such as ...

Recent Posts. MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025 January 24, 2025; Why fact-checking is important in the rare disease world January 21, 2025; PFF hosts Broadway fundraising event for pulmonary fibrosis January 17, 2025; The Los Angeles fires remind us to be prepared for emergencies January 14, 2025; Blocking HIF2 protein may promote lung repair in IPF: Mouse ...

2 days ago · An imbalance in gene activity within two types of immune cells explains why idiopathic pulmonary fibrosis (IPF) progresses but in people who develop lung fibrosis after a severe COVID-19 infection, their lungs get better, a new study finds. Researchers showed mortality risk in IPF and COVID-19 was ...

Sep 27, 2024 · FIBRONEER-IPF (NCT05321069) enrolled 1,177 patients, ages 40 and older, at several sites in the U.S., Canada, South America, Europe, Asia, and Australia. Full efficacy and safety data will be presented in the first half of 2025. The company intends to seek the nerandomilast’s approval for IPF to the U.S. Food and Drug Administration (FDA) and other regulatory agencies worldwide.

Jun 7, 2024 · The trial also assessed the effects of treatment on key measures of lung fibrosis as assessed by high-resolution computed tomography (HRCT). Results showed treatment with ENV-101 significantly decreased the absolute percent of quantitative interstitial lung disease — which measures the extent of lung fibrosis — by 9.4%, compared with a 1.1% increase in the placebo.

Nov 8, 2024 · “These results are an important step forward in the development of our lead asset, CAL101, particularly for fibrotic and fibro-inflammatory diseases where there remains a critical need for innovative therapeutic options,” Jonas Hallén MD, PhD, co-founder and chief medical officer of Calluna, said in a company press release.. Fibrosis, or scarring, plays a major role in many diseases and ...

Nov 22, 2024 · The Pulmonary Fibrosis Foundation (PFF) has launched “PF Basics: Info for Newly Diagnosed Patients,” a new educational program to help patients with pulmonary fibrosis (PF) and interstitial lung disease get answers to the most pressing questions about their disease after a recent diagnosis.

Nov 7, 2017 · One of my frustrations as a pulmonary fibrosis patient is finding solid information about what to expect as my PF progresses. I’ve asked several doctors what to expect during the end stage of PF, but often get the same answer: “We’re not there, no need to talk about that now.” I want to talk about the end stage